Expression Pathology, MD Anderson Evaluating Technology for Lung Cancer Therapy Selection | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology today announced a collaboration with the University of Texas MD Anderson Cancer Center for the evaluation of the company's Liquid Tissue SRM technology.

Specifically, the deal is for the evaluation of the technology for matching the most appropriate targeted therapies with lung cancer patients.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: sequencing technique to uncover plant disease-resistance genes, and more.

In a Science Translational Medicine opinion piece, a Merck executive suggests that universities offer money-back guarantees on their research.

NantKwest's Patrick Soon-Shiong received some $148 million in compensation in 2015.

With sequencing moving toward applications, Illumina CEO Francis deSouza says his company has even more to offer, Fast Company reports.